- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
-
Protalix's New Drug Likely to Win FDA Approval
-
Is IBB the Best Biotech ETF?
-
Genzyme: The Next Big Biotech Machine
-
The Bug in Genzyme's Side
-
Passport Capital Chooses Gold over Education
-
Adult Stem Cell Drugs and Therapies Are the Next Big Market
-
Options Trader: Wednesday Outlook
-
Fast Money Recap: Mister Softee No More? (6/16/09)
-
Wall Street Breakfast: Must-Know News
-
Proposed Legislation Could Boost Medicare's Ability to Extract Savings on Drugs
-
FDA and Clinical Trial Updates: ADLS, CLDA, GENZ, ISTA, Theratech
-
Q1 2009 Biotech Earnings Roundup: The Good, the Bad, and the Ugly
-
Highlighting Best and Worst Analyst Rated Stocks
-
FDA, Clinical Trial Updates: Genzyme, Human Genome Sciences, Eli Lilly, NeurogesX
-
FDA, Clinical Trial Updates: Heart Stents, Cholesterol in the News
-
Isis, Genzyme May Have a Winning Drug
-
Best Analyst Ratings in the S&P 500
-
FDA, Clinical Trial Calendar Updates: WYE, SVNT, AMRN, ISIS, SLXP, SOMX
-
Sequenom Splattered, Exact Sciences Could Benefit
-
Weekly Street Sentiment: Where Have All the Reasonable People Gone?
-
Apple and the QQQ ETF: High-Beta, Growth-Oriented, Tech-Driven Exposure
-
FDA, Clinical Trial Calendar Updates: Genzyme, Isis, Osiris, Roche, Watson
-
Stocks with the Most Buy and Sell Recommendations
-
Impax Labs: Strong Balance Sheet, Focused R&D
-
Rally Broaches Resistance: What the Charts Say
-
Opportunities in Healthcare: Highly Defensive Stocks
-
Tracking Cancer Diagnostic and Therapeutic Stocks
-
EXACT Sciences: Becoming Tempting
-
Business Trends: Coke and Pepsi, Genzyme, Mortgage Bankers, Autos, Health Insurance
-
Market Volatility and Equity Betas
-
Osiris Hits a Speedbump in Crohn's Program
-
Biotech M&A Action: We've Only Just Begun
-
2 Potential Pharma M&A Targets: Cephalon and Genzyme
-
Thursday's Options Recap
-
Where Might Genentech Investors Redeploy $47B?
-
Big Mergers Could Mean Sweet Gains for Biotech
-
Biotech Is Now the Place to Be for Big Pharma
-
Biotech Dip: Sector Weakness, or Buying Opportunity?
-
With Funding Ban Lifted, Stem Cell Index Soars
-
Biotech Going Generic Like Big Pharma?
-
Market Goes Down, Biotech and Healthcare Lead the Way